Bora Pharmaceuticals Co., Ltd. (TPE:6472)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
346.00
+10.00 (2.98%)
May 29, 2026, 1:30 PM CST

Bora Pharmaceuticals Cash Flow Statement

Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
1,6082,9813,8533,0301,392749.74
Depreciation & Amortization
999.931,024968.8563.53285.23185.31
Other Amortization
62.0862.0857.5342.7639.9524.85
Loss (Gain) From Sale of Assets
-43.79-43.5427.9953.382.22
Asset Writedown & Restructuring Costs
-135.83151.42----
Loss (Gain) From Sale of Investments
-394.27-2,965-11.561,04447.79-0.78
Loss (Gain) on Equity Investments
461.46452.960.04---
Stock-Based Compensation
67.1478.62135.98102.8131.8315.77
Other Operating Activities
900.862,317-833.44317.17205.67309.69
Change in Accounts Receivable
469.211,149-1,3722,157-1,509-282.39
Change in Inventory
1,0872,051-341.82-124.599.39172.37
Change in Accounts Payable
87.09140.29-663.52-90.88107.179.81
Change in Unearned Revenue
57.11131.619.31134.72-11.7716.36
Change in Other Net Operating Assets
-1,035-1,285-505.36-2,5691,31833.68
Operating Cash Flow
3,7754,504980.024,6142,0101,237
Operating Cash Flow Growth
240.61%359.54%-78.76%129.53%62.54%595.56%
Capital Expenditures
-1,067-928.67-528.1-297.71-194.81-163.48
Sale of Property, Plant & Equipment
6.176.1112.593.3737.950.08
Cash Acquisitions
-489.5-620.21-10,265-999.99-4,514-3.83
Divestitures
-0.2-1,004--24-
Sale (Purchase) of Intangibles
-50.95-43.98-158.95-1,132-5.41-200.1
Investment in Securities
-1,164-1,092422.21-41.7323.98-
Other Investing Activities
214.08303.68-162.4410.9247.49141.48
Investing Cash Flow
-2,552-3,380-10,680-2,458-4,281-225.85
Short-Term Debt Issued
-1,3701,824-772.33-
Long-Term Debt Issued
-46015,0214,8045,554100
Total Debt Issued
3,8491,83016,8444,8046,327100
Short-Term Debt Repaid
----1,398--572.17
Long-Term Debt Repaid
--1,410-2,910-5,176-1,916-172.03
Total Debt Repaid
-3,101-1,410-2,910-6,574-1,916-744.2
Net Debt Issued (Repaid)
748.31419.3713,934-1,7694,411-644.2
Issuance of Common Stock
112.37127.5594.8933.943.966.91
Repurchase of Common Stock
-119.28-139.26-389.13--53.09-
Common Dividends Paid
-1,449-1,449-1,233-619.13-238.8-109.77
Other Financing Activities
-332.28-335.65-336.63-85.72471.9-54.34
Financing Cash Flow
-1,040-1,37712,071-2,4404,595-741.4
Foreign Exchange Rate Adjustments
-476.62-499.34404.8656.1346.89-28.63
Net Cash Flow
-293.62-752.312,776-228.032,371240.76
Free Cash Flow
2,7073,575451.924,3161,8151,073
Free Cash Flow Growth
367.97%691.04%-89.53%137.76%69.15%3657.55%
Free Cash Flow Margin
14.60%18.80%2.59%30.39%17.30%21.90%
Free Cash Flow Per Share
14.4018.953.2034.7415.339.19
Cash Interest Paid
266.74266.74382.69156.01105.0454.12
Cash Income Tax Paid
474.88474.881,057896.47367.7518.16
Levered Free Cash Flow
1,3262,901-4,5793,1481,037625.48
Unlevered Free Cash Flow
1,6253,204-4,2793,2551,105658.99
Change in Working Capital
665.362,188-2,863-491.944.31-50.16